M ultiple sclerosis (MS) is a T cell-mediated autoimmune disease characterized by the infiltration of inflammatory leukocytes, including macrophages and T cells, into the CNS, resulting in myelin damage (1) . Clinical improvement in MS patients is commonly observed during pregnancy, suggesting that elevated levels of sex steroid hormones exert immunoregulatory activity, thereby inhibiting the autoimmune response and/or inflammation (2) (3) (4) . Indeed, studies of estrogen's effects on experimental autoimmune encephalomyelitis (EAE), a murine model of MS, have shown that 17b-estradiol (E2) administration inhibits disease development (5, 6) . Likewise, a protective effect of estrogens has been reported in a pilot clinical trial using estriol administration to MS patients (7, 8) . These diseasemodulating effects of exogenous estrogens in MS and its experimental model, EAE, may account for the beneficial effects of pregnancy on clinical symptoms in women with MS.
E2 actions are essentially mediated by two intracellular molecular targets: estrogen receptor (ER) a and ERb. We and others have shown that the protective effect of E2 on EAE was mediated through ERa (9) (10) (11) . E2-mediated EAE protection has been associated with immunoregulatory effects characterized by a strong inhibition of autoantigen-specific Th responses, including both Th1 (6, 9, 10, 12) and Th17 cells (13) . Although it was initially thought that these anti-inflammatory effects of E2 were mediated through a direct action on T lymphocytes (12, 14) , it has been subsequently suggested that myeloid cells, such as dendritic cells (DCs), rather than T cells, were the primary targets of estrogens responsible for the immunoregulatory effects of E2 leading to EAE protection (15, 16) . Thus, despite the obvious impacts of estrogens on CNS autoimmunity, the ERa-expressing cell types that mediate the anti-inflammatory effect of E2 on EAE are not known.
In the present work, we sought to identify the cellular target of E2 in an experimental model in which E2 treatment induces complete and long-lasting EAE protection and is associated with a strong inhibition in autoantigen-specific Th1 and Th17 cell responses and CNS inflammation (6, 9, 10) . To this end, we conditionally deleted ERa from the endothelial or the hema-*INSERM, U1043, Toulouse F-31300, France; † Centre National de la Recherche Scientifique, U5282, Toulouse F-31300, France; ‡ Centre de Physiopathologie de Toulouse Purpan, Université Paul Sabatier, Université de Toulouse, Toulouse F-31300, France; topoietic compartments, from macrophages, DCs, or T lymphocytes, and evaluated the protective effect of E2 on EAE in such mice. Despite the broad expression of ERa among immune cells, we unexpectedly found that the E2-mediated inhibition of Th17-driven CNS autoimmunity relies selectively on ERa expressed in T lymphocytes.
Materials and Methods

Mice
Female C57BL/6JRJ (B6) mice were purchased from the Centre d'Elevage R. Janvier (Le Genest St. Isle, France) and maintained in our animal facilities under pathogen-free conditions. Mice with a disrupted Esr1 gene, hererafter called ERa ) with B6 mice expressing the Cre recombinase under the control of the Tie2 promoter-enhancer (18) or the lysozyme M (LysM) promoter (19) . These mice have been described elsewhere (20) (21) (22) . The targeted exon 2 of the Esr1 gene sites encodes the first zinc finger of the DNA binding domain of ERa. Cre-mediated recombination of the conditional floxed allele leads to unambiguous inactivation of ERa (17) . To generate mice selectively lacking ERa in DC or T lymphocytes, we crossed ERa fl/fl mice with mice expressing the Cre recombinase under the control of CD11c (23) or CD4 (24) promoter, respectively.
Southern blot analysis
Genomic DNA (10 mg) obtained from various tissues or from purified CD4 + T lymphocytes were digested with BamHI restriction enzyme (Invitrogen), electrophoresed on a 1% agarose gel, and transferred to positively charged nylon membranes (MP Biomedicals). A previously described ERa probe (P39) (17) was radiolabeled with (a-[ 32 P]) dCTP (Amersham Biosciences). The membrane was hybridized overnight at 42˚C then washed twice with 23 SSC, 0.1% SDS, for 10 min at room temperature and once with 0.13SSC, 0.5% SDS, for 10-30 min at 52˚C. Autoradiography was performed by exposing the blots to medical x-ray film (Agfa) at 280˚C for 1 to 2 wk. The 4.4-kb and 8.8-kb bands represent the targeted (floxed) allele and the deleted allele, respectively (17) .
Quantitative real-time PCR
Purified CD4
+ T cells were homogenized in TRIzol reagent (Invitrogen Life Technologies, San Diego, CA), and RNA was extracted following the manufacturer's instructions. RNA samples (1 mg) were treated with DNase I (Invitrogen Life Technologies) and transcribed into cDNA using random primers and Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies). Reactions were performed in a 25 ml final volume using the SYBR Green PCR Master Mix (Eurogentec). Gene expression level was quantified using ABI Prism 7900 sequence detection system (Applied Biosystems). ERa-specific primer sequences have been described elsewhere (21) . Results were analyzed using the SDS program, version 2.2 (Applied Biosystems). The relative expression of target transcripts in each sample was normalized to HPRT according to the DCt method.
EAE induction and treatment
For active EAE induction, mice were immunized s.c. in the flanks with 100 mg myelin oligodendrocyte glycoprotein (MOG)35-55 peptide (Neosystem, Strasbourg, France) emulsified in IFA supplemented with 4 mg/ml Mycobacterium tuberculosis (H37RA; Sigma-Aldrich, St. Louis, MO). Mice were injected i.p. with 200 ng pertussis toxin (Calbiochem, Darmstadt, Germany) at days 0 and 2 and examined daily for clinical signs of disease. The mice were scored as follows: 0, no detectable signs of EAE; 1, complete limp tail; 2, limp tail and hindlimb weakness; 3, severe hindlimb weakness; 4, complete bilateral hindlimb paralysis; 5, complete hindlimb paralysis and forelimb weakness; 5.5, total paralysis of both forelimbs and hindlimbs; and 6, death.
For E2 treatment, we used the standard protocol described by others (9, 10) . Briefly, female mice were implanted s.c. in the scapular region with an E2 pellet (2.5 mg, 60-d release; Innovative Research of America) 7 d before immunization with MOG35-55 peptide as described above for EAE induction. Unless otherwise stated, 8-12-wk-old mice were used in all experiments. All the protocols used have been approved by our institutional review board for animal experimentation.
T cell assays
Mice were immunized in the flank with MOG35-55/CFA as for EAE induction. Seven to 12 d postimmunization, draining lymph nodes or spleens were harvested. For the recall assay with lymph node cells (LNC), total LNC were stimulated in vitro with the indicated concentrations of MOG35-55 peptide or Con A (Sigma-Aldrich) in HL-1 synthetic medium as described elsewhere (25) . Splenic CD4 + T cells were purified using the Dynal mouse CD4 negative isolation kit (Invitrogen) and then cultured at 3 
Flow cytometric analysis of CNS-infiltrating cells and intracellular cytokine staining
On the indicated day postimmunization, mice were anesthetized and perfused intracardiacally with ice-cold PBS. The brain and spinal cord were resected and then homogenized and digested for 30 min with collagenase D (Roche, Indianapolis, IN) and DNase I (Roche) under continuous agitation at 37˚C. The cell suspension was then strained through a 70-mm nylon filter (Falcon) and washed with HBSS containing 20 mM HEPES. Cells were separated by centrifugation (2000 rpm for 30 min) on a discontinuous isotonic Percoll gradient containing 90% and 30% layers. Mononuclear cells at the 90-30% interface were collected, resuspended in HBSS-HEPES, and washed extensively in FACS buffer containing 1% FCS, 5 mM EDTA, and 0.1% NaN 3 in PBS. For flow cytometry, cells were stained with PE anti-CD45.2, FITC-labeled anti-CD11b, and allophycocyaninanti-CD4 mAbs, all purchased from BD Pharmingen. For intracellular cytokine staining, CNS-infiltrating cells were stimulated for 4 h with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 5 mg/ml brefeldin A (Sigma-Aldrich). Cells were cell surface stained with anti-CD4-APC, fixed, and permeabilized. Cells were stained intracellularly with FITCanti-IFN-g mAb and PE-conjugated anti-mouse IL-17, TNF-a, or IL-4 mAbs (BD Biosciences).
For intracellular cytokine staining of MOG-specific CD4 + T cells, purified splenic CD4 + T lymphocytes were stimulated for 18 h at 37˚C with irradiated (1700 rad) syngeneic splenocytes with 10 mM MOG35-55 in the presence of 5 mg/ml brefeldin A (Sigma-Aldrich) for the last 4 h of culture. Cells were cell surface stained with anti-CD4 and anti-CD44 mAbs, fixed, and permeabilized. Cells were then stained intracellularly with FITC-anti-IFN-g mAb and PE-conjugated anti-mouse IL-17 or TNF-a mAbs (BD Biosciences).
Data were collected on an FACSCalibur cytometer (BD Biosciences) and analyzed using Flowjo software (Tree Star, Ashland, OR). 
Generation of bone marrow chimeras
ERa
2/2 B6 recipients. Eight weeks after reconstitution, mice were implanted or not with 2.5 mg E2 pellet 1 wk before immunization with MOG peptide to induce EAE as described above.
Histology, immunochemistry, and stereology
Mice were anesthetized and perfused intracardiacally with PBS and then paraformaldehyde 2%. Intact spinal columns were removed and fixed in 4% buffered formalin. The spinal cords were dissected and embedded in paraffin before sectioning. Ten-micrometer-thick sections were stained with anti-CD45 mAb followed by HRP-labeled anti-rat IgG secondary Abs using standard procedure. The slides were counterstained with hematoxylin to visualize nuclei and analyzed by light microscopy.
Structural quantification of the infiltrates was done on ∼8-10 random step sections cut perpendicular to the longitudinal spinal cord axis by means of an unbiased stereologic approach. The entire spinal cross sections were captured with a digital camera on a Nikon Eclipse E600 microscope (Nikon) with a magnification of 34, resulting in approximately four images per cross section. A test grid composed of lines and points was superimposed on these digital images using the STEPanizer stereology tool (27) . Volume density (V/ V ) was assessed by counting test points and the count recorded with the STEPanizer. Each point represented an area on the section and therefore a volume (density) in three dimensions. The volume density was afterward correlated to the surface area density (S/ V ) of the spinal cord, assessed by counting intersections of a test line with the spinal profile border, S/ V = 2 I/ L , in which I is the number of intersections with the border and L the length of the test lines. This relation resulted in an absolute metric value, V/ V / S/ V = V/ S , with metric units mm 
Statistical analysis
For comparison of EAE clinical scores between groups, repeated measures two-way ANOVA was performed followed by a Bonferroni post hoc test by using GraphPad Prism 4 (GraphPad Software, La Jolla, CA). Otherwise, pairwise comparisons between groups were conducted using the MannWhitney U test. All graphs show mean 6 SEM.
Results
The anti-inflammatory effect of E2 on EAE is exclusively dependent on ERa and is lost in mice lacking ERa in both endothelium and hematopoietic cells Using a well-established model of E2-mediated EAE protection (6, 9), we first evaluated the role of ERa using mutant mice exhibiting a fully disrupted Esr1 gene (17, 28) . Whereas administration of E2 1 wk before EAE induction markedly reduced disease incidence and severity in ERa +/+ C57BL/6 mice, it had no effect on EAE development in ERa 2/2 mice (Fig. 1A) . These data confirmed previous works (9, 10) and establish that pharmacological activation of ERa by E2 is required to prevent EAE development in this experimental setting. As a first step to identify the primary ERa-expressing cellular target responsible for the protective action of estrogens on EAE, we assessed the effect of E2 treatment on EAE development in Tie2-ERa KO mice in which the floxed ERa gene is conditionally invalidated in both endothelial and hematopoietic cells after crossing with Cre-expressing mice under the control of the Tie2 promoter (20, 21) . As shown in Fig. 1B (Fig. 1B) . Although a slight delay in disease onset was observed in E2-treated mice, EAE subsequently developed in this group with similar incidence and severity as compared with untreated mice (Fig. 1B The Journal of Immunologywhereas no obvious differences were observed between control and E2-treated Tie2-ERa KO animals (Supplemental Fig. 1) . Indeed, analysis of the phenotype of CNS infiltrates in diseased Tie2-ERa KO animals treated or not with E2 showed no overt change in the cellular profile of mononuclear cells with regard to the percentage of CD4 + T cells and macrophages or microglia (Supplemental Fig. 2C, 2D) . Likewise, the frequency of pathogenic IL-17-producing CD4 + T cells (Supplemental Fig. 2E ) was similar in both groups.
The protective effect of E2 treatment against EAE in control ERa fl/fl mice was associated with a strong inhibition of the proliferative response and the production of IFN-g and IL-17 by splenic CD4 + T lymphocytes in response to MOG peptide (Fig.  1C) . This immunoregulatory effect of E2 was lost in Tie2-ERa KO mice that developed similar proliferative responses and produced comparable amounts of both cytokines whether they were treated with E2 or not (Fig. 1C) . These results strongly suggest that ERa activation in the endothelial and/or hematopoietic compartments downregulated EAE by limiting MOG-specific priming and differentiation of encephalitogenic Th1 and Th17 lymphocytes.
ERa expression in hematopoietic cells is required for E2-mediated EAE protection
To assess whether the protective effect of E2 on EAE was dependent on the expression of ERa in blood-derived hematopoietic cells, radiation BM chimeras were generated. Lethally irradiated WT B6 or Tie2-ERa KO recipients were reconstituted with BM cells from either ERa 2/2 or WT mice. Whereas E2-mediated EAE inhibition was maintained in control WT → WT or WT → Tie2-ERa KO BM chimeras ( Fig. 2A) , the protective action of E2 was lost in WT or Tie2-ERa KO mice reconstituted with ERa 2/2 BM cells (Fig. 2B) . In this latter combination, despite some delay in disease onset in E2-treated mice, EAE then developed with similar incidence and severity as compared with untreated controls. Altogether, these data show that ERa expressed in hematopoietic cells rather than endothelial cells is required for the protective effect of exogenous E2 on EAE.
ERa signaling in monocytes/macrophages or DCs is dispensable for E2-mediated EAE protection
Hematopoietic cells, including encephalitogenic T cells, bloodderived macrophages, and DCs, are important triggers of inflammation during CNS autoimmunity (29, 30) . To explore their respective roles in E2-mediated EAE protection, we first analyzed the effect of ERa inactivation in the APC compartment, including monocytes/macrophages and conventional DCs (cDCs). We recently generated mice selectively lacking ERa in monocyte/ macrophages by crossing ERa fl/fl mice with mice expressing the Cre recombinase specifically in the myeloid compartment, driven by the LysM promoter (22) . LysM-ERa KO mice and their respective negative littermate controls (ERa fl/fl ) developed clinical EAE with similar incidence, time of onset, and severity (Fig. 3A,  3B ), indicating that ERa activation in monocytes/macrophages by endogenous estrogens had no measurable impact on the induction and progression of CNS autoimmunity. Administration of exogenous E2, however, prevented EAE development (Fig. 3A) and CNS inflammation (data not shown) with similar efficacy in both groups. Likewise, the proliferative response of MOG-specific T cell in the draining LNC as well as the production of IFN-g and IL-17 were strongly inhibited in both E2-treated ERa fl/fl and LysM-ERa KO mice (Fig. 3C, 3D) . Thus, these results show that ERa signaling in monocytes/macrophages was dispensable for the E2-mediated inhibition of encephalitogenic Th1/Th17 cell development and EAE protection.
Because it has been suggested that estrogens may program DCs to become tolerogenic (15, 31), we generated mice lacking ERa in the cDC compartment by crossing ERa fl/fl B6 mice with mice expressing the Cre recombinase under the control of a CD11c transgenic locus (23) . Disease course and overall severity were similar between CD11c-ERa KO and ERa fl/fl littermate controls, showing that inactivation of ERa in the cDC compartment does not modify clinical EAE in female mice (Fig. 4A) . Administration of E2 in CD11c-ERa KO resulted in a complete inhibition of EAE development over a 30-d observation period (Fig. 4B ). These data, together with our data in the LysM-Cre system, indicate that ERa signaling in professional APCs, including monocyte-derived DCs 
T lymphocytes are the main in vivo cellular targets of E2 mediating the inhibition of encephalitogenic CD4 + T cell priming and EAE protection Lastly, because E2 treatment had such a profound inhibitory effect on the priming of encephalitogenic CD4 + T cells, we assessed whether a T cell-intrinsic mechanism was involved. For this, we generated mice in which ERa was specifically invalidated in T cells (CD4-ERa KO ) by crossing CD4-Cre transgenic mice with ERa fl/fl B6 mice. As expected, we observed complete Cremediated excision of the ERa gene in CD4 + T lymphocytes but not in nonlymphoid tissues (Supplemental Fig. 3 ). We next compared the effect of E2 treatment on EAE induction in CD4-ERa KO mice and their respective ERa fl/fl littermate controls. In the absence of E2 treatment, EAE developed with similar incidence, time of onset, and severity in both groups of mice (Table  II) . Whereas E2 treatment strongly inhibited EAE in control ERa fl/fl mice, long-term E2-mediated EAE protection was lost in the majority of CD4-ERa KO animals (Fig. 5A , Table II ). Although there was still a significant delay in disease onset and the peaking of the disease (Table II) in E2-treated CD4-ERa KO mice, maximum disease scores were comparable to untreated CD4-ERa KO or ERa fl/fl mice (Table II) . In agreement with clinical data, histological analysis of spinal cord sections of E2-treated CD4-ERa KO mice demonstrated strong CD45 + immune cell infiltrates in their CNS (Fig. 5B, 5C ). Of note, stereological assessment of the CD45 + spinal cord infiltrates actually showed a significant increase in the number of inflammatory cells in the spinal cord of E2-treated CD4-ERa KO mice as compared with untreated controls (Fig. 5C ). By contrast, E2-treated ERa fl/fl littermate controls, which were protected from EAE, were devoid of inflammatory infiltrates at the same time point (Fig. 5B, 5C ). Analysis of the MOG-specific T cell responses in draining lymph nodes of CD4-ERa KO mice demonstrated that E2 treatment was unable to inhibit MOG-specific CD4 + T cell proliferation and development into IFN-g-and IL-17-producing T cells if ERa was not expressed in T cells (Fig. 5D) .
In similar experiments, we also analyzed the frequency of MOG-specific splenic CD4 + T cells producing Th1 and Th17 effector cytokines. Upon stimulation of purified CD4 + T cells with MOG35-55 peptide and irradiated syngeneic APC for 18 h, MOG-specific cytokine producing cells were detected among the CD4 + CD44 hi memory populations (Supplemental Fig. 4 ). In agreement with the data presented in Fig. 5 , the percentages of MOG-specific CD4 + T cells producing IFN-g, IL-17, or TNF-a were strongly reduced in E2-treated ERa fl/fl mice as compared with untreated controls (Fig. 6A) . By contrast, E2 treatment was ineffective at preventing MOG-specific Th1 or Th17 cell differentiation in CD4-ERa KO mice (Fig. 6B) . Altogether, these data show that E2 treatment inhibits the differentiation of MOGspecific CD4 + T cells into Th1 and Th17 cells in vivo through a mechanism that requires ERa expression in T lymphocytes.
To be able to pinpoint the cellular requirement for ERa signaling in the hematopoietic compartment, we next generated BM chimeras into Rag2 (Fig. 7) . In striking contrast, in mice reconstituted with BM cells from CD4-ERa KO mice, EAE development was unaffected by E2 treatment, and disease developed with similar time of onset, incidence, and severity as in untreated ERa fl/fl mice or E2-treated chimeras reconstituted with ERa 2/2 BM cells (Fig. 7) . Altogether, these data firmly establish that activation of ERa by E2 in T lymphocytes is necessary and sufficient to mediate the inhibition of EAE development in the absence of extrahematopoietic ERa.
Discussion
Despite strong evidence that E2 or estriol have beneficial effects on the clinical signs of MS and EAE, little is known about the E2-responsive target cells orchestrating the anti-inflammatory action of exogenous estrogens in peripheral lymphoid organs. Given that ER are expressed, though at different levels, in almost all tissues of the body, estrogen may influence CNS autoimmunity through its action on various cell types involved in multiple aspects of immune responses and inflammation. Indeed, it has been hypothesized that estrogen-induced protection in EAE could be mediated through several nonexclusive mechanisms, including direct or indirect effects on autoreactive T cells (6, 9, 10, 12) , induction of Treg cells (14) , modulation of APC functions (15, 16, 31) , or direct neuroprotective effects in the CNS through ERaand/or ERb-mediated signaling in astrocytes (32, 33) or microglia (34, 35) . In the present work, using newly created cell-type specific ERa-deficient mice in combination with BM chimera experiments, we demonstrate conclusively that ERa expressed in conventional T lymphocytes is the main mediator of the antiinflammatory action of exogenous E2 on EAE through its capacity to inhibit Th1/Th17 priming in secondary lymphoid tissues. These results are unexpected given previous results obtained by us and others that suggested that the anti-inflammatory action of E2 in EAE was not mediated directly by E2-responsive T cells, but rather through indirect effects on myeloid cells or other tissues (11, 15, 16) . Indeed, in an adoptive EAE model, it was shown that ERa expression in encephalitogenic T cells was not required for E2-mediated EAE protection (16) . Likewise, we previously reported that low-dose E2 administration could prevent acute EAE development in the absence of ERa expression in peripheral T cells (11) . In this latter model, however, disease protection was not associated with immunomodulatory effects on autoantigenspecific CD4 T cell responses in vivo (11) . Thus, differences in the dose of hormone and timing of administration may explain the discrepancies regarding the anti-inflammatory effects of E2 on T cell priming (6, 9, 11) . Our data now demonstrate, in a wellestablished model of E2-mediated EAE protection (6, 9, 10) , that ligand-inducible activation of ERa in T lymphocytes mediates the inhibition of Th1 and Th17 development, resulting in complete protection from CNS inflammation. This conclusion is supported by several lines of evidence. First, we established that hematopoietic ERa accounts for most of the anti-inflammatory effect of exogenous E2 on EAE and that E2 can operate in the complete absence of ERa in the host's nonhematopoietic compartment. Second, by monitoring the E2 effect in conditional knockout mouse strains selectively lacking ERa in distinct immune cell populations, we provide evidence that ERa signaling was required in T lymphocytes, but not in monocytes/macrophages or DCs, for sustained inhibition of EAE. Lastly, in the absence of ERa in the host's nonhematopoietic tissues, we showed that selective ERa inactivation in T cells abolished the protective effects of exogenous E2 on EAE development, thereby demonstrating the unique and nonredundant role of ERa signaling in T cells. Collectively, these data support the hypothesis that ERa signaling in T lymphocytes suppresses Th1/Th17 cell priming and CNS autoimmunity through a mechanism of immunoregulation that occurs in the secondary lymphoid tissues.
It has been suggested that estrogens may directly act on myeloid cells, such as DCs, to promote their development into tolerogenic DCs responsible for the anti-inflammatory effect of E2 in EAE (15, 31) . Although we cannot exclude that these cells may be ultimately involved in the immunoregulatory mechanisms leading to inhibition of Th1 and Th17 cell priming in immune lymph nodes, our data now show that ERa expressed in monocyte/macrophages and cDCs does not represent the primary target of E2 in vivo. Additionally, E2 might act on nonhematopoietic cells, such as endothelial cells or CNS-resident cells (i.e., astrocytes), to reduce encephalitogenic T cell trafficking to the CNS and/or ongoing autoimmune inflammation (11, (32) (33) (34) 36) . Although these mechanisms may cooperate together to limit and/or delay EAE development in some situations, they do not seem to be sufficient for full EAE protection in the absence of the T cell driven antiinflammatory action of E2.
ERs not only function as ligand-activated transcription factors but can also mediate their effects through the rapid activation of cytoplasmic signal transduction pathways (37) . Although ERa can mediate both classical genomic as well as rapid nongenomic responses to E2 (38) , it has been recently suggested that the orphan G protein-coupled receptor 30 (GPR30) could be responsible for the mediation of membrane initiated nongenomic effects of E2 (39) . A recent study in the EAE model has shown that administration of the GPR30 agonist G-1 conferred protection from EAE in WT but not in GPR30-deficient mice (40) . However, a strong protective effect of E2 still persisted in GPR30-deficient mice, suggesting that ERa rather than GPR30 represented the main receptor targeted by E2 (40) . Indeed, the role of GPR30 as a putative membrane ER has been recently challenged by studies demonstrating that GPR30 did not bind E2 (41) and was not necessary to induce the effects of estrogen in the reproductive tissues (42) . Although it cannot be excluded that GPR30 and ERa could act in concert in some signal transduction pathways (43) , the GPR30-dependent mechanisms of EAE protection could involve distinct cellular targets from those responsible for the suppressive effect of E2 on EAE.
In conclusion, our data emphasize a major role for ERa signaling in T lymphocytes in the anti-inflammatory effect of E2 and protection against CNS autoimmunity. We show that most of the anti-inflammatory effects of estrogens are due to the inhibition of encephalitogenic Th1 and Th17 cell development in lymph nodes through ERa expressed in T lymphocytes. Although the molecular and cellular mechanisms by which T cell-intrinsic ERa signaling regulates Th1/Th17 differentiation remain to be characterized, our results add ERa to the growing list of nuclear receptors that have been shown to modulate Th cell differentiation (44) (45) (46) (47) . Understanding the cellular and molecular mechanisms by which ERa signaling in T lymphocytes mediates the anti-inflammatory effect of E2 may help to design selective ER modulators with T cell-specific agonist properties, but devoid of harmful effects on reproductive tissues, for specific intervention in Th1/Th17-mediated autoimmune diseases such as MS.
